EUVIMEDEUVIMED entdecken
Crossref

Rapid Development of High Concentration Protein Formulation Driven by High-Throughput Technologies

Lun Xin, Monika Prorok, Zhe Zhang, Guilherme Barboza, Rahul More, Michael Bonfiglio, Lv Cheng, Kevin Robbie, Steven Ren, Yunsong Li

Pharmaceutical Research · 2025

DOI: 10.1007/s11095-024-03801-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2025. Verfasst von Lun Xin und 9 weiteren Autor:innen. Beteiligte Einrichtung: BioDev Department WuXi Biologics USA, 1 Cedarbrook Dr, Cranbury, NJ, 08512, USA. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, Antibodies, Monoclonal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: High concentration protein formulation (HCPF) development needs to balance protein stability attributes such as conformational/colloidal stability, chemical stability, and solution properties such as viscosity and osmolality. METHODOLOGY: A three-phase design is established in this work. In Phase 1, conformational and colloidal stability are measured by 384-well-based high-throughput (HT) biophysical screening while viscosity reduction screening is performed with HT viscosity screening. Collectively, the biophysical and viscosity screening data are leveraged to design the phase 2 of short-term stability study, executed using 96-well plates under thermal and freeze/thaw stresses. In phase 2, samples are analyzed by stability-indicating assays and processed with pair-wise Student's t-test analyses to choose the final formulations. In phase 3, the final formulations are then confirmed through a one-month accelerated stability in glass vials. RESULTS: Using a model antibody A (mAb-A), the initial HT screening successfully established the 384-well based platform. A lead formulation was chosen from the second round based on statistical analyses and subsequently tested against the commercial formulation of mAb-A as a control. Compared to the control, the lead formulation reduced the viscosity of mAb-A by 30% and decreased subvisible particles after thermal stress by 80%. CONCLUSIONS: HT biophysical screening in 384-well plates was demonstrated to effectively guide the rational design of a high-throughput stability screening study using 96-well plates. This platform enables the identification of a high concentration formulation within seven weeks within the first two phases of study that strategically balance stability with solution properties, thus achieving a rapid development of HCPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Screening AssaysAntibodies, MonoclonalViscosityProtein StabilityDrug StabilityDrug CompoundingChemistry, Pharmaceutical

Stichwörter der Autor:innen

384-well based biophysical screeningchip-based tangential flow filtration (µTFF)high concentration protein formulation (HCPF)statistical analysesviscosity

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • BioDev Department WuXi Biologics USA, 1 Cedarbrook Dr, Cranbury, NJ, 08512, USA.
  • CMC Management, WuXi Biologics, Cranbury, NJ, USA.
  • BioDev Department WuXi Biologics USA, 1 Cedarbrook Dr, Cranbury, NJ, 08512, USA. Yunsong.li@WuXibiologics.com.

Zitieren

APA

Xin, L., Prorok, M., Zhang, Z., Barboza, G., More, R., Bonfiglio, M., Cheng, L., Robbie, K., Ren, S., & Li, Y. (2025). Rapid Development of High Concentration Protein Formulation Driven by High-Throughput Technologies. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03801-3

Vancouver

Xin L, Prorok M, Zhang Z, Barboza G, More R, Bonfiglio M, et al. Rapid Development of High Concentration Protein Formulation Driven by High-Throughput Technologies. Pharmaceutical Research. 2025. doi:10.1007/s11095-024-03801-3

BibTeX
@article{Xin2025,
  author = {Xin, Lun and Prorok, Monika and Zhang, Zhe and Barboza, Guilherme and More, Rahul and Bonfiglio, Michael and Cheng, Lv and Robbie, Kevin and Ren, Steven and Li, Yunsong},
  title = {Rapid Development of High Concentration Protein Formulation Driven by High-Throughput Technologies},
  journal = {Pharmaceutical Research},
  year = {2025},
  doi = {10.1007/s11095-024-03801-3}
}
Kostenlos starten →